Abstract
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality and healthcare expenditure in patients with chronic liver disease. The management of HCC is evolving because of recently introduced novel therapeutic approaches. Optimal outcome requires an early and accurate assessment of tumor response to therapy. Current imaging modalities, such as computed tomography (CT) and magnetic resonance (MR) imaging; provide reliable and reproducible anatomical data in order to demonstrate tumor burden changes. However, in the setting of novel targeted therapies and liver directed treatments, simple tumor anatomical changes can be less informative and usually appear later than biological changes. There has been a growing interest to monitor the therapeutic response, at an early phase of treatment, by measuring tumor viability and/or perfusion. Therefore the importance of tumor viability assessment is increasingly being recognized. The tumor viability measurement guidelines have recently been amended to include the measurement of only the longest diameter of the enhancing tumors to formally amend RECIST to modified RECIST (mRECIST). Viable tumor should be defined as uptake of contrast agent in the arterial phase. In thi...Continue Reading
References
Feb 2, 2000·Baillière's Best Practice & Research. Clinical Gastroenterology·W T Yang, P J Johnson
Oct 11, 2001·Journal of Hepatology·J BruixUNKNOWN EASL Panel of Experts on HCC
Oct 21, 2005·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·John P Roberts
Mar 15, 2006·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Anthony F Shields
May 23, 2007·AJR. American Journal of Roentgenology·Dow-Mu Koh, David J Collins
Apr 29, 2009·Gastroentérologie Clinique Et Biologique·A HollebecqueS Dharancy
Dec 22, 2009·Cancer Biology & Therapy·Mark A Rosen
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Apr 17, 2010·Journal of Hepatology·Morris Sherman
Jun 30, 2011·Cancer·Julien EdelineJean-Luc Raoul
Nov 4, 2011·The Lancet Oncology·Pierre-Alain ClavienUNKNOWN OLT for HCC Consensus Group
Sep 5, 2012·Journal of Hepatology·Tao JiangDushyant V Sahani
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C VerslypeUNKNOWN ESMO Guidelines Working Group
Citations
Mar 8, 2016·Journal of Oncology·Nathan HaywoodDerek A DuBay
Feb 9, 2016·Diagnostics·Christina SchramlKonstantin Nikolaou
Feb 9, 2016·Diagnostics·Johannes M LudwigHyun S Kim
Jan 23, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Ting YuLin Lin
Mar 24, 2016·Abdominal Radiology·Yanhua TangHuiyi Ye
Sep 3, 2016·Cancers·Eric Van CutsemThomas Seufferlein
Nov 14, 2017·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Khaled M ElsayesClaude B Sirlin
Feb 25, 2020·Cancer Medicine·Han ZhouJianji Pan
Apr 9, 2020·Medical Oncology·Enrico Maria FumarolaGianpaolo Carrafiello
Mar 12, 2020·Cancer Management and Research·Qiaojuan GuoShaojun Lin
May 31, 2016·World Journal of Gastroenterology : WJG·Ke YangJuan Peng
Apr 24, 2018·Abdominal Radiology·Aventinus NörthenThomas Rodt
Mar 28, 2019·Therapeutic Advances in Gastroenterology·Arno Kornberg, Helmut Friess
Apr 1, 2016·Hepatic Oncology·Tim Ch HoogenboomRohini Sharma
Mar 12, 2019·Oncology Letters·Maiko YoshidaYuta Shibamoto
Oct 21, 2019·Archives of Virology·Ines DhifallahOlfa Bahri
Feb 7, 2020·Journal of Clinical and Experimental Hepatology·Ashish KumarUNKNOWN INASL Task-Force on Hepatocellular Carcinoma
Oct 26, 2021·Cardiovascular and Interventional Radiology·Pierleone LucatelliThomas Helmberger